ProQR Announces Closing of Underwritten Public Offering and Concurrent Private PlacementGlobeNewsWire • 10/25/24
ProQR Prices $75 Million Underwritten Public Offering and Concurrent Private PlacementGlobeNewsWire • 10/23/24
ProQR Highlights Upcoming Presentation at 20th Annual Meeting of the Oligonucleotide Therapeutics SocietyGlobeNewsWire • 10/07/24
ProQR Announces Webcast Presentation at the 2024 Cantor Global Healthcare ConferenceGlobeNewsWire • 09/10/24
ProQR Nominates Martin Maier, PhD to Board and Announces Annual Meeting of Shareholders to be Held May 22, 2024GlobeNewsWire • 04/23/24
ProQR Highlights Upcoming Presentations on Axiomer™ RNA Editing at ASGCT 27th Annual MeetingGlobeNewsWire • 04/22/24
ProQR Achieves Successful Defense of New Challenge to its Axiomer™ IP PortfolioGlobeNewsWire • 04/19/24
ProQR Highlights New Platform Data from Presentation on Axiomer™ RNA Editing Technology at Deaminet 2024GlobeNewsWire • 01/19/24
ProQR and Rett Syndrome Research Trust Join Forces with Axiomer™ RNA Editing CollaborationGlobeNewsWire • 01/05/24
ProQR Therapeutics Announces Transaction Completed for Théa to Acquire Sepofarsen and Ultevursen Ophthalmic AssetsGlobeNewsWire • 12/08/23
ProQR Strengthens Leading Intellectual Property Estate for ADAR-mediated RNA EditingGlobeNewsWire • 11/06/23
ProQR Announces Participation in the Chardan 7th Annual Genetic Medicines ConferenceGlobeNewsWire • 09/28/23
ProQR Announces Webcast of Presentation at the Upcoming HC Wainwright 25th Annual Global Investment ConferenceGlobeNewsWire • 09/07/23
ProQR Therapeutics and Laboratoires Théa Announce Agreement for Théa to Acquire ProQR's Sepofarsen and Ultevursen Ophthalmic AssetsGlobeNewsWire • 08/01/23
ProQR to Present Data on its Axiomer® RNA Editing Technology at RNA Editing SummitGlobeNewsWire • 07/06/23